LISA PHARMA: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
LISA PHARMA
Largest movements
- Receivables within one year +€56,220
up €56,220 (+70.7%), from €79,501 to €135,721
of which Trade receivables: +€84,925
- Debts after one year -€87,856
down €87,856 (-47.5%), from €185,069 to €97,213
- Trade debts +€65,870
up €65,870 (+53.2%), from €123,917 to €189,787
- Profit (loss) carried forward +€25,740
up €25,740 (+320%), from €8,042 to €33,782
- Other debts +€24,243
new in 2025: €24,243
- Tax, wage and social debts +€15,810
up €15,810 (+126%), from €12,564 to €28,374
of which Taxes: +€27,904
- Gross operating margin -€63,693
down €63,693 (-36.8%), from €173,043 to €109,350
- Staff costs -€12,362
down €12,362 (-19.5%), from €63,392 to €51,030
- Financial charges -€5,054
down €5,054 (-27.2%), from €18,611 to €13,556
- Taxes -€4,540
no longer reported in 2025 (was €4,540)
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Cash or the result is not a separate line in both sets of accounts; the cash flow cannot be derived from them.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €541,739 | €597,067 | +€55,328 | +10.2% |
| Fixed assets | 21/28 | €353,344 | €352,436 | -€909 | -0.3% |
| Tangible fixed assets | 22/27 | €351,794 | €350,758 | -€1,036 | -0.3% |
| Land and buildings | 22 | €199,007 | €184,390 | -€14,617 | -7.3% |
| Plant, machinery and equipment | 23 | €143,703 | €158,183 | +€14,480 | +10.1% |
| Furniture and vehicles | 24 | €9,083 | €8,185 | -€899 | -9.9% |
| Financial fixed assets | 28 | €1,551 | €1,678 | +€127 | +8.2% |
| Current assets | 29/58 | €188,395 | €244,631 | +€56,236 | +29.9% |
| Stocks and contracts in progress | 3 | €81,305 | €81,305 | = | 0.0% |
| Stocks | 30/36 | €81,305 | €81,305 | = | 0.0% |
| Amounts receivable within one year | 40/41 | €79,501 | €135,721 | +€56,220 | +70.7% |
| Trade receivables | 40 | €48,346 | €133,271 | +€84,925 | +176% |
| Other amounts receivable | 41 | €31,154 | €2,449 | -€28,705 | -92.1% |
| Current investments | 50/53 | €25,966 | €25,982 | +€16 | +0.1% |
| Deferred charges and accrued income | 490/1 | €1,624 | €1,624 | = | 0.0% |
| Total equity and liabilities | 10/49 | €541,739 | €597,067 | +€55,328 | +10.2% |
| Equity | 10/15 | €127,632 | €153,372 | +€25,740 | +20.2% |
| Contributions | 10/11 | €18,550 | €18,550 | = | 0.0% |
| Reserves | 13 | €101,040 | €101,040 | = | 0.0% |
| Tax-exempt reserves | 132 | €101,040 | €101,040 | = | 0.0% |
| Profit (loss) carried forward | 14 | €8,042 | €33,782 | +€25,740 | +320% |
| Amounts payable | 17/49 | €414,107 | €443,695 | +€29,588 | +7.1% |
| Amounts payable after more than one year | 17 | €185,069 | €97,213 | -€87,856 | -47.5% |
| Financial debts | 170/4 | €185,069 | €97,213 | -€87,856 | -47.5% |
| Amounts payable within one year | 42/48 | €213,659 | €346,482 | +€132,823 | +62.2% |
| Current portion of amounts payable after more than one year | 42 | €74,724 | €87,673 | +€12,949 | +17.3% |
| Financial debts | 43 | €2,453 | €16,404 | +€13,951 | +569% |
| Credit institutions | 430/8 | €2,453 | €16,404 | +€13,951 | +569% |
| Trade debts | 44 | €123,917 | €189,787 | +€65,870 | +53.2% |
| Suppliers | 440/4 | €123,917 | €189,787 | +€65,870 | +53.2% |
| Taxes, remuneration and social security | 45 | €12,564 | €28,374 | +€15,810 | +126% |
| Taxes | 450/3 | - | €27,904 | +€27,904 | |
| Remuneration and social security | 454/9 | €12,564 | €470 | -€12,094 | -96.3% |
| Other amounts payable | 47/48 | - | €24,243 | +€24,243 | |
| Accrued charges and deferred income | 492/3 | €15,380 | - | -€15,380 | |
| Remuneration, social security and pensions | 62 | €63,392 | €51,030 | -€12,362 | -19.5% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €18,388 | €17,580 | -€808 | -4.4% |
| Other operating charges | 640/8 | €1,268 | €1,459 | +€192 | +15.1% |
| Gross operating margin | 9900 | €173,043 | €109,350 | -€63,693 | -36.8% |
| Operating profit (loss) | 9901 | €89,995 | €39,280 | -€50,715 | -56.4% |
| Financial income | 75/76B | - | €16 | +€16 | |
| Recurring financial income | 75 | - | €16 | +€16 | |
| Financial charges | 65/66B | €18,611 | €13,556 | -€5,054 | -27.2% |
| Recurring financial charges | 65 | €18,611 | €13,556 | -€5,054 | -27.2% |
| Profit (loss) for the period before taxes | 9903 | €71,385 | €25,740 | -€45,645 | -63.9% |
| Income taxes | 67/77 | €4,540 | - | -€4,540 | |
| Profit (loss) for the period | 9904 | €66,845 | €25,740 | -€41,105 | -61.5% |
| Profit (loss) for the period to be appropriated | 9905 | €66,845 | €25,740 | -€41,105 | -61.5% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 16 October 2026 via checked.be.